Title
Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
Document Type
Article
Publication Date
4-1-2019
Publication Title
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Clinical Institute
Cancer
Department
Earle A. Chiles Research Institute
Department
Oncology
Department
Pulmonary Medicine
Recommended Citation
Horn, L; Whisenant, J G; Wakelee, H; Reckamp, K L; Qiao, H; Du, L; Hernandez, J; Huang, V; Waqar, S N; Patel, S; Sanborn, R E; Shaffer, T; Garg, K; Holzhausen, A; Harrow, K; Liang, C; Lim, L P; Li, M; and Lovly, C M, "Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)." (2019). Articles, Abstracts, and Reports. 2895.
https://digitalcommons.providence.org/publications/2895